

May 26, 2017

To,  
National Securities Exchange of India Limited  
Listing Department  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir,

**Trading Symbol: ZOTA**

**Sub: Product Registration in Myanmar**

**Ref.: Regulation 30(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015**

Pursuant to Regulation 30(3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 this is to inform you that Company has received product registration for below mentioned three products from Myanmar.

Name of Product	Therapeutic Category
LORGIC 10 (Tab. loratidine 10 mg)	Antihistamine (Nonsedating)
PANTOZED 40 (Cap. Pantoprazole 40 mg)	Antiulcer (Gastrointestinal)
ZOTAMET 500 (Tab. Metformin 500 mg)	Antidiabetic

Company shall start exporting these three products in Myanmar very soon.

This is for your information and record.

Yours faithfully,

For **Zota Health Care Limited**

  
  
**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
Place: Surat

**Corporate Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122